We have found only little data concerning the effect of CDK4/6 inhibition in ER-negative breast cancers; a phase II study of palbociclib monotherapy in advanced heavily pretreated breast cancer recruited four cases with triple-negative disease, none of which experienced a response [68]. The gene discussed is CDK4; the disease is breast carcinoma.